Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 19;14(10):2509.
doi: 10.3390/cancers14102509.

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer

Camille Domergue  1 , Elodie Martin  2 , Camille Lemarié  3 , Pascal Jézéquel  4 , Jean-Sebastien Frenel  5 , Paule Augereau  1 , Mario Campone  1 , Anne Patsouris  1
Affiliations

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer

Camille Domergue et al. Cancers (Basel). .

Abstract

Purpose: Investigates the link between HER2 status and histological response after neoadjuvant chemotherapy in patients with early TNBC.

Methods: We retrieved clinical and anatomopathological data retrospectively from 449 patients treated for the first time with standard neoadjuvant chemotherapy for early unilateral BC between 2005 and 2020. The primary endpoint was pathological complete response (pCR, i.e., ypT0 ypN0), according to HER2 status. Secondary endpoints included invasive disease-free survival (I-DFS) and overall survival (OS).

Results: 437 patients were included, and 121 (27.7%) patients had HER2-low tumours. The pCR rate was not significantly different between the HER2-low group vs. the HER2-0 group (35.7% versus 41.8%, p = 0.284) in either univariate analysis or multivariate analysis adjusted for TNM classification and grade (odds ratio [OR] = 0.70, confidence interval [CI] 95% 0.45-1.08). With a median follow-up of 72.9 months, no significant survival differences were observed between patients with HER2-low tumours vs. patients with HER2-0 tumours in terms of I-DFS (p = 0.487) and OS (p = 0.329).

Conclusions: In our cohort, HER2 status was not significantly associated with pCR in a manner consistent with data published recently on TNBC. However, the prognostic impact of HER2-low expression among TNBC patients warrants further evaluation.

Keywords: HER2-low; complete histologic response; prognosis; triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CONSORT diagram of the study.
Figure 2
Figure 2
Outcomes data according to HER2 status (HER2-low versus HER-0). (A) OS, (B) I-DFS.
See this image and copyright information in PMC

References

    1. Freres P., Collignon J., Gennigens C., Scagnol I., Rorive A., Barbeaux A., Coucke P.A. Jérusalem Gle cancer du sein «triple né-gatif». Rev. Med. Liège. 2010;65:120–126. - PubMed
    1. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N. Engl. J. Med. 2007;357:2666–2676. doi: 10.1056/NEJMoa072113. - DOI - PubMed
    1. Nabholtz J.M., Abrial C., Mouret-Reynier M.-A., Dauplat M.M., Weber B., Gligorov J., Forest A.M., Tredan O., Vanlemmens L., Petit T., et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: Identification of biologically defined signatures predicting treatment impact. Ann. Oncol. 2014;25:1570–1577. doi: 10.1093/annonc/mdu183. - DOI - PubMed
    1. Mateo J., Lord C.J., Serra V., Tutt A., Balmaña J., Castroviejo-Bermejo M., Cruz C., Oaknin A., Kaye S.B., de Bono J.S. A decade of clinical development of PARP inhibitors in perspective. Ann. Oncol. 2019;30:1437–1447. doi: 10.1093/annonc/mdz192. - DOI - PMC - PubMed
    1. Tutt A.N., Garber J.E., Kaufman B., Viale G., Fumagalli D., Rastogi P., Gelber R.D., de Azambuja E., Fielding A., Balmaña J., et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med. 2021;384:2394–2405. doi: 10.1056/NEJMoa2105215. - DOI - PMC - PubMed